Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2009

01.06.2009 | Review

Use of antioxidant supplements during breast cancer treatment: a comprehensive review

verfasst von: Heather Greenlee, Dawn L. Hershman, Judith S. Jacobson

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose An estimated 45–80% of breast cancer patients use antioxidant supplements after diagnosis, and use of antioxidant supplements during breast cancer treatment is common. Dietary supplements with antioxidant effects include vitamins, minerals, phytonutrients, and other natural products. We conducted a comprehensive review of literature on the associations between antioxidant supplement use during breast cancer treatment and patient outcomes. Methods Inclusion criteria were: two or more subjects; clinical trial or observational study design; use of antioxidant supplements (vitamin C, vitamin E, antioxidant combinations, multivitamins, glutamine, glutathione, melatonin, or soy isoflavones) during chemotherapy, radiation therapy, and/or hormonal therapy for breast cancer as exposures; treatment toxicities, tumor response, recurrence, or survival as outcomes. Results We identified 22 articles that met those criteria. Their findings did not support any conclusions regarding the effects of individual antioxidant supplements during conventional breast cancer treatment on toxicities, tumor response, recurrence, or survival. A few studies suggested that antioxidant supplements might decrease side effects associated with treatment, including vitamin E for hot flashes due to hormonal therapy and glutamine for oral mucositis during chemotherapy. Underpowered trials suggest that melatonin may enhance tumor response during treatment. Conclusion The evidence is currently insufficient to inform clinician and patient guidelines on the use of antioxidant supplements during breast cancer treatment. Thus, well designed clinical trials and observational studies are needed to determine the short- and long-term effects of such agents.
Literatur
1.
Zurück zum Zitat American Cancer Society (2008) Breast cancer facts & figures 2007–2008. Atlanta, American Cancer Society, Inc American Cancer Society (2008) Breast cancer facts & figures 2007–2008. Atlanta, American Cancer Society, Inc
2.
Zurück zum Zitat Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26:665–673CrossRefPubMed Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26:665–673CrossRefPubMed
3.
Zurück zum Zitat Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4CrossRefPubMed Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4CrossRefPubMed
4.
Zurück zum Zitat Buettner C, Kroenke CH, Phillips RS et al (2006) Correlates of use of different types of complementary and alternative medicine by breast cancer survivors in the nurses’ health study. Breast Cancer Res Treat 100:219–227CrossRefPubMed Buettner C, Kroenke CH, Phillips RS et al (2006) Correlates of use of different types of complementary and alternative medicine by breast cancer survivors in the nurses’ health study. Breast Cancer Res Treat 100:219–227CrossRefPubMed
5.
Zurück zum Zitat Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10:52–57PubMed Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10:52–57PubMed
6.
Zurück zum Zitat Navo MA, Phan J, Vaughan C et al (2004) An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22:671–677CrossRefPubMed Navo MA, Phan J, Vaughan C et al (2004) An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22:671–677CrossRefPubMed
7.
Zurück zum Zitat Ashikaga T, Bosompra K, O’Brien P et al (2002) Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer 10:542–548CrossRefPubMed Ashikaga T, Bosompra K, O’Brien P et al (2002) Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer 10:542–548CrossRefPubMed
8.
Zurück zum Zitat Lengacher CA, Bennett MP, Kip KE et al (2002) Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 29:1445–1452CrossRefPubMed Lengacher CA, Bennett MP, Kip KE et al (2002) Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 29:1445–1452CrossRefPubMed
9.
Zurück zum Zitat Patterson RE, Neuhouser ML, Hedderson MM et al (2002) Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8:477–485CrossRefPubMed Patterson RE, Neuhouser ML, Hedderson MM et al (2002) Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8:477–485CrossRefPubMed
10.
Zurück zum Zitat Demark-Wahnefried W, Peterson B, McBride C et al (2000) Current health behaviors and readiness to pursue lifestyle changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer 88:674–684CrossRefPubMed Demark-Wahnefried W, Peterson B, McBride C et al (2000) Current health behaviors and readiness to pursue lifestyle changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer 88:674–684CrossRefPubMed
11.
Zurück zum Zitat VandeCreek L, Rogers E, Lester J (1999) Use of alternative therapies among breast cancer outpatients compared with the general population. Altern Ther Health Med 5:71–76PubMed VandeCreek L, Rogers E, Lester J (1999) Use of alternative therapies among breast cancer outpatients compared with the general population. Altern Ther Health Med 5:71–76PubMed
12.
Zurück zum Zitat Newman V, Rock CL, Faerber S et al (1998) Dietary supplement use by women at risk for breast cancer recurrence. The Women’s Healthy Eating and Living Study Group. J Am Diet Assoc 98:285–292CrossRefPubMed Newman V, Rock CL, Faerber S et al (1998) Dietary supplement use by women at risk for breast cancer recurrence. The Women’s Healthy Eating and Living Study Group. J Am Diet Assoc 98:285–292CrossRefPubMed
13.
14.
Zurück zum Zitat D’Andrea GM (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 55:319–321CrossRefPubMed D’Andrea GM (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 55:319–321CrossRefPubMed
18.
Zurück zum Zitat Hellman S (1993) Principles of radiation therapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. J. B. Lippincott Co, Philadelphia Hellman S (1993) Principles of radiation therapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. J. B. Lippincott Co, Philadelphia
21.
Zurück zum Zitat Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134:S3201–S3204 Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134:S3201–S3204
23.
Zurück zum Zitat Simone CB II, Simone NL, Simone V et al (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 2. Altern Ther Health Med 13:40–47PubMed Simone CB II, Simone NL, Simone V et al (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 2. Altern Ther Health Med 13:40–47PubMed
24.
Zurück zum Zitat Simone CB II, Simone NL, Simone V et al (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med 13:22–28PubMed Simone CB II, Simone NL, Simone V et al (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med 13:22–28PubMed
25.
Zurück zum Zitat Labriola D, Livingston R (1999) Possible interactions between dietary antioxidants and chemotherapy. Oncology (Williston Park) 13:1003–1008 (discussion 1008, 1011-1002) Labriola D, Livingston R (1999) Possible interactions between dietary antioxidants and chemotherapy. Oncology (Williston Park) 13:1003–1008 (discussion 1008, 1011-1002)
26.
Zurück zum Zitat Moore HC, Green SJ, Gralow JR et al (2007) Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol 25:1677–1682. doi:10.1200/JCO.2006.08.9383 CrossRefPubMed Moore HC, Green SJ, Gralow JR et al (2007) Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol 25:1677–1682. doi:10.​1200/​JCO.​2006.​08.​9383 CrossRefPubMed
27.
Zurück zum Zitat Poulter JM, White WF, Dickerson JW (1984) Ascorbic acid supplementation and five year survival rates in women with early breast cancer. Acta Vitaminol Enzymol 6:175–182PubMed Poulter JM, White WF, Dickerson JW (1984) Ascorbic acid supplementation and five year survival rates in women with early breast cancer. Acta Vitaminol Enzymol 6:175–182PubMed
28.
Zurück zum Zitat Martin-Jimenez M, Diaz-Rubio E, Gonzalez Larriba JL et al (1986) Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin. N Engl J Med 315:894–895PubMed Martin-Jimenez M, Diaz-Rubio E, Gonzalez Larriba JL et al (1986) Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin. N Engl J Med 315:894–895PubMed
29.
Zurück zum Zitat Perez JE, Macchiavelli M, Leone BA et al (1986) High-dose alpha-tocopherol as a preventive of doxorubicin-induced alopecia. Cancer Treat Rep 70:1213–1214PubMed Perez JE, Macchiavelli M, Leone BA et al (1986) High-dose alpha-tocopherol as a preventive of doxorubicin-induced alopecia. Cancer Treat Rep 70:1213–1214PubMed
30.
Zurück zum Zitat Weitzman SA, Lorell B, Carey RW et al (1980) Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity. Curr Ther Res 28:682–686 Weitzman SA, Lorell B, Carey RW et al (1980) Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity. Curr Ther Res 28:682–686
32.
Zurück zum Zitat Lenzhofer R, Ganzinger U, Rameis H et al (1983) Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment. J Cancer Res Clin Oncol 106:143–147. doi:10.1007/BF00395393 CrossRefPubMed Lenzhofer R, Ganzinger U, Rameis H et al (1983) Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment. J Cancer Res Clin Oncol 106:143–147. doi:10.​1007/​BF00395393 CrossRefPubMed
33.
Zurück zum Zitat Barton DL, Loprinzi CL, Quella SK et al (1998) Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16:495–500PubMed Barton DL, Loprinzi CL, Quella SK et al (1998) Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16:495–500PubMed
34.
Zurück zum Zitat Hoffer A, Pauling L (1990) Hardin Jones biostatistical analysis of mortality data for cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomol Med 5:143–154 Hoffer A, Pauling L (1990) Hardin Jones biostatistical analysis of mortality data for cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomol Med 5:143–154
35.
Zurück zum Zitat Hoffer A, Pauling L (1993) Hardin Jones biostatistical analysis of mortality data for a second set of cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomol Med 8:157–167 Hoffer A, Pauling L (1993) Hardin Jones biostatistical analysis of mortality data for a second set of cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomol Med 8:157–167
36.
Zurück zum Zitat Lockwood K, Moesgaard S, Hanioka T et al (1994) Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15:S231–S240. doi:10.1016/0098-2997(94)90033-7 CrossRefPubMed Lockwood K, Moesgaard S, Hanioka T et al (1994) Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15:S231–S240. doi:10.​1016/​0098-2997(94)90033-7 CrossRefPubMed
37.
38.
Zurück zum Zitat Premkumar VG, Yuvaraj S, Vijayasarathy K et al (2007) Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull 30:367–370. doi:10.1248/bpb.30.367 CrossRefPubMed Premkumar VG, Yuvaraj S, Vijayasarathy K et al (2007) Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull 30:367–370. doi:10.​1248/​bpb.​30.​367 CrossRefPubMed
40.
Zurück zum Zitat Li Y, Yu Z, Liu F et al (2006) Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Tumori 92:396–401PubMed Li Y, Yu Z, Liu F et al (2006) Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Tumori 92:396–401PubMed
41.
Zurück zum Zitat Peterson DE, Jones JB, Petit RGII (2007) Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 109:322–331. doi:10.1002/cncr.22384 CrossRefPubMed Peterson DE, Jones JB, Petit RGII (2007) Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 109:322–331. doi:10.​1002/​cncr.​22384 CrossRefPubMed
42.
Zurück zum Zitat Nobile MT, Vidili MG, Benasso M et al (1989) A preliminary clinical study of cyclophosphamide with reduced glutathione as uroprotector. Tumori 75:257–258PubMed Nobile MT, Vidili MG, Benasso M et al (1989) A preliminary clinical study of cyclophosphamide with reduced glutathione as uroprotector. Tumori 75:257–258PubMed
44.
Zurück zum Zitat Lissoni P, Barni S, Mandala M et al (1999) Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35:1688–1692. doi:10.1016/S0959-8049(99)00159-8 CrossRefPubMed Lissoni P, Barni S, Mandala M et al (1999) Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35:1688–1692. doi:10.​1016/​S0959-8049(99)00159-8 CrossRefPubMed
45.
Zurück zum Zitat Lissoni P, Barni S, Meregalli S et al (1995) Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71:854–856PubMed Lissoni P, Barni S, Meregalli S et al (1995) Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71:854–856PubMed
46.
Zurück zum Zitat Quella SK, Loprinzi CL, Barton DL et al (2000) Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 18:1068–1074PubMed Quella SK, Loprinzi CL, Barton DL et al (2000) Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 18:1068–1074PubMed
47.
Zurück zum Zitat Van Patten CL, Olivotto IA, Chambers GK et al (2002) Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 20:1449–1455. doi:10.1200/JCO.20.6.1449 CrossRefPubMed Van Patten CL, Olivotto IA, Chambers GK et al (2002) Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 20:1449–1455. doi:10.​1200/​JCO.​20.​6.​1449 CrossRefPubMed
48.
Zurück zum Zitat MacGregor CA, Canney PA, Patterson G et al (2005) A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 41:708–714. doi:10.1016/j.ejca.2005.01.005 CrossRefPubMed MacGregor CA, Canney PA, Patterson G et al (2005) A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 41:708–714. doi:10.​1016/​j.​ejca.​2005.​01.​005 CrossRefPubMed
49.
Zurück zum Zitat Block KI, Koch AC, Mead MN et al (2008) Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 123:1227–1239. doi:10.1002/ijc.23754 CrossRefPubMed Block KI, Koch AC, Mead MN et al (2008) Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 123:1227–1239. doi:10.​1002/​ijc.​23754 CrossRefPubMed
50.
51.
Zurück zum Zitat Bairati I, Meyer F, Gelinas M et al (2005) A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97:481–488PubMedCrossRef Bairati I, Meyer F, Gelinas M et al (2005) A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97:481–488PubMedCrossRef
52.
Zurück zum Zitat Kwan ML, Ambrosone CB, Lee MM et al (2008) The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control. doi:10.1007/s10552-008-9170-5 Kwan ML, Ambrosone CB, Lee MM et al (2008) The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control. doi:10.​1007/​s10552-008-9170-5
53.
Zurück zum Zitat Greenlee H, Kwan ML, Krathwohl SE et al (2008) History of CAM use in a prospective breast cancer cohort study. In: Presented at 4th biennial cancer survivorship research conference, 18–20 June 2008, Atlanta, GA (abstr 1794) Greenlee H, Kwan ML, Krathwohl SE et al (2008) History of CAM use in a prospective breast cancer cohort study. In: Presented at 4th biennial cancer survivorship research conference, 18–20 June 2008, Atlanta, GA (abstr 1794)
54.
Zurück zum Zitat Greenlee H, Gammon MD, Abrahamson PE et al (2007) Use of supplemental antioxidants after breast cancer diagnosis and during breast cancer treatment among women with breast cancer in the Long Island Breast Cancer Study Project. In: Presented at society for integrative oncology 4th international conference, 15–17 November 2007, San Francisco CA (abstr 18157) Greenlee H, Gammon MD, Abrahamson PE et al (2007) Use of supplemental antioxidants after breast cancer diagnosis and during breast cancer treatment among women with breast cancer in the Long Island Breast Cancer Study Project. In: Presented at society for integrative oncology 4th international conference, 15–17 November 2007, San Francisco CA (abstr 18157)
55.
Zurück zum Zitat Albanes D, Heinonen OP, Huttunen JK et al (1995) Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62:1427S–1430SPubMed Albanes D, Heinonen OP, Huttunen JK et al (1995) Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62:1427S–1430SPubMed
56.
57.
Zurück zum Zitat van Dalen EC, Caron HN, Dickinson HO et al (2008) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2:CD003917PubMed van Dalen EC, Caron HN, Dickinson HO et al (2008) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2:CD003917PubMed
59.
Metadaten
Titel
Use of antioxidant supplements during breast cancer treatment: a comprehensive review
verfasst von
Heather Greenlee
Dawn L. Hershman
Judith S. Jacobson
Publikationsdatum
01.06.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0193-0

Weitere Artikel der Ausgabe 3/2009

Breast Cancer Research and Treatment 3/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.